Insight, China's Pharmaceutical Industry

GSK’s Risvutatug Rezetecan Wins Japan ODD – B7-H3 ADC Targets Small-Cell Lung Cancer with Phase 1 Durable Responses

GlaxoSmithKline (GSK; NYSE: GSK) announced that risvutatug rezetecan (Ris-Rez), a B7-H3-targeted antibody-drug conjugate (ADC), received...

Company Deals Drug

Belief BioMed Partners with Grand Life Sciences on BBM-H803 – AAV Gene Therapy for Hemophilia A Targets Greater China Market

Fineline Cube Mar 24, 2026

Belief BioMed (“BBM”) and Grand Life Sciences Group Co., Ltd. (HKG: 0512) announced an exclusive...

Company Deals

Hanmi Pharmaceutical Partners with Chongqing Zhongfu – Amlodipine/Losartan Fixed-Dose Combo Targets China Out-of-Hospital Digital Market

Fineline Cube Mar 24, 2026

Hanmi Pharmaceutical (South Korea) announced a partnership with Chongqing Zhongfu Pharmaceutical Co., Ltd. to jointly...

Company Deals

Sinomune Pharma Licenses Seysara from Almirall – Exclusive China Rights to Tetracycline Acne Antibiotic

Fineline Cube Mar 24, 2026

Sinomune Pharmaceutical Co., Ltd., a China-based dermatological specialist, announced a licensing agreement with Almirall, S.A....

Company Deals

Chipscreen Biosciences Licenses Epidaza to Nizhpharm – $29M Deal Expands HDAC Inhibitor into Central Asia and Eastern Europe

Fineline Cube Mar 24, 2026

Shenzhen Chipscreen Biosciences Co., Ltd. (SHA: 688321) announced a licensing agreement with Nizhny Novgorod Chemical...

Company Deals

Tenacia Bio Licenses Ztalmy to Golden Age Health – Bain-Backed CNS Specialist Partners on Rare Epilepsy Drug in China

Fineline Cube Mar 24, 2026

Tenacia Biopharmaceuticals (Shanghai) Co., Ltd., a Bain Capital-incubated CNS specialist, announced a licensing agreement with...

Company Deals

Formosa Pharmaceuticals Licenses APP13007 to Arrotex – Nanoparticle Ophthalmic Steroid Gains Australia/New Zealand Rights

Fineline Cube Mar 24, 2026

Formosa Pharmaceuticals (TPE: 6838) announced a licensing agreement with Arrotex Pharmaceuticals Pty Ltd., granting the...

Company Deals

Rapport Therapeutics Licenses RAP-219 to Tenacia Bio – $328M Deal Targets Greater China Epilepsy and Bipolar Markets

Fineline Cube Mar 24, 2026

Rapport Therapeutics, Inc. (NASDAQ: RAPP) announced a licensing agreement with Tenacia Biopharmaceuticals (Shanghai) Co., Ltd....

Company Deals

LexBio Partners with Hiteck Biopharma – AI-Enabled Drug Discovery Alliance Targets Inflammatory Disease Small Molecules

Fineline Cube Mar 24, 2026

Suzhou Langrui Biopharmaceutical Co., Ltd. (LexBio), an AI-enabled drug development biotech, announced a strategic partnership...

Company Deals

Chongqing Maile Bio-Pharm Partners with Main Luck Pharma on Hematoporphyrin Commercialization – Photodynamic Therapy Targets Superficial Cancers

Fineline Cube Mar 24, 2026

Chongqing Maile Bio-Pharm Co. Ltd. and Shenzhen Main Luck Pharmaceuticals Inc. announced a strategic partnership...

Company Deals

Shanghai Pharmaceuticals Licenses MCB-166 Antidepressant from SJTU – Novel Mechanism Drug Candidate Targets Mental Health Pipeline

Fineline Cube Mar 24, 2026

Shanghai Pharmaceuticals (HKG: 2607, SHA: 601607), China’s pharmaceutical distribution leader, announced a licensing agreement with...

Company

Insilico Medicine Launches PandaClaw – AI Agent Platform Transforms Biological Research with Natural Language Interface

Fineline Cube Mar 24, 2026

Insilico Medicine (HKG: 3696) announced the launch of PandaClaw, a transformative new feature of its...

Company Deals

Insilico Medicine Partners with ASKA Pharma – AI‑Driven Target Discovery Collaboration Targets Gynecological Diseases

Fineline Cube Mar 24, 2026

Insilico Medicine (HKG: 3696) announced a strategic drug discovery collaboration with ASKA Pharmaceutical Co., Ltd.,...

Company Drug

Qilu Pharma’s QLS1317 Wins NMPA Approval – First‑in‑Class MSI‑H Targeted Therapy Enters Solid Tumor Clinical Trials

Fineline Cube Mar 24, 2026

Qilu Pharmaceutical Co., Ltd. announced that its self‑developed Category 1 innovative drug, QLS1317 tablets, has...

Policy / Regulatory

NHSA Unveils DRG 3.0 Grouping Scheme Roadmap – Systematic Upgrade Targets 2027 Implementation

Fineline Cube Mar 24, 2026

China’s National Healthcare Security Administration (NHSA) held a briefing outlining the DRG (Diagnosis‑Related Groups) Grouping...

Company Deals

Biocytogen Partners with Moonlight Bio – Antibody‑Cell Therapy Collaboration Targets Difficult‑to‑Treat Cancers

Fineline Cube Mar 24, 2026

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (SHA: 688796, HKG: 2315) has entered into a strategic partnership...

Company Drug

Innovent’s IBI302 Hits STAR Trial Primary Endpoint – Dual VEGF/Complement Inhibitor Shows 16‑Week Dosing and 50% Macular Atrophy Reduction in nAMD

Fineline Cube Mar 24, 2026

Innovent Biologics, Inc. (HKG: 1801) announced that its Phase III STAR study (NCT05972473) evaluating efdamrofusp...

Company Deals

Bio‑Thera Expands Intas Partnership to India – BAT2506 Golimumab Biosimilar Now Licensed Across US, Canada, and India

Fineline Cube Mar 24, 2026

Bio‑Thera Solutions Inc. (SHA: 688177) has expanded its strategic partnership with Intas Pharmaceuticals Ltd., granting...

Company

Sanofi Upgrades Shanghai R&D Center to Legal Entity – Largest China Translational Medicine Hub Anchors Global Network

Fineline Cube Mar 24, 2026

Sanofi S.A. (NASDAQ: SNY) announced a comprehensive strategic upgrade of its China R&D center, establishing...

Company Drug

RemeGen Secures Fourth NMPA Approval for Disitamab Vedotin – HER2‑Low Breast Cancer with Liver Metastases Indication Expands ADC Franchise

Fineline Cube Mar 24, 2026

RemeGen Co., Ltd. (SHA: 688331, HKG: 9995) announced NMPA approval for a new indication of...

Insight, China's Pharmaceutical Industry

Salubris Pharma Licenses Sintanovo’s Peripherally Restricted KOR Agonist STC007 for Pruritus and Pain Across Greater China

China’s Largest Healthcare M&A Fund Acquires Pediatrix Therapeutics, Bolstering Pediatric Specialty Pharma Portfolio

Insilico Medicine and Eli Lilly Forge $2.75B AI Drug Discovery Partnership, Centered on Best-in-Class Oral Therapeutic

Novartis to Acquire Excellergy for Up to $2 Billion, Adding Next-Gen Anti-IgE Antibody Exl-111 to Immunology Pipeline

Huahai Pharma and Almirall Strike $340M Monoclonal Antibody Licensing Deal Targeting Dermatology and Beyond

Hansoh Pharma’s Uplizna Gains Third NMPA Approval in China for Generalized Myasthenia Gravis, Expanding CD19 Antibody Franchise

Huadong Medicine’s YY001 Becomes World’s First Recombinant Botulinum Toxin Approved in China for Glabellar Lines

GSK’s Risvutatug Rezetecan Wins Japan ODD – B7-H3 ADC Targets Small-Cell Lung Cancer with Phase 1 Durable Responses

Belief BioMed Partners with Grand Life Sciences on BBM-H803 – AAV Gene Therapy for Hemophilia A Targets Greater China Market

Hanmi Pharmaceutical Partners with Chongqing Zhongfu – Amlodipine/Losartan Fixed-Dose Combo Targets China Out-of-Hospital Digital Market

Sinomune Pharma Licenses Seysara from Almirall – Exclusive China Rights to Tetracycline Acne Antibiotic

Chipscreen Biosciences Licenses Epidaza to Nizhpharm – $29M Deal Expands HDAC Inhibitor into Central Asia and Eastern Europe

Tenacia Bio Licenses Ztalmy to Golden Age Health – Bain-Backed CNS Specialist Partners on Rare Epilepsy Drug in China

Formosa Pharmaceuticals Licenses APP13007 to Arrotex – Nanoparticle Ophthalmic Steroid Gains Australia/New Zealand Rights

Rapport Therapeutics Licenses RAP-219 to Tenacia Bio – $328M Deal Targets Greater China Epilepsy and Bipolar Markets

LexBio Partners with Hiteck Biopharma – AI-Enabled Drug Discovery Alliance Targets Inflammatory Disease Small Molecules

Chongqing Maile Bio-Pharm Partners with Main Luck Pharma on Hematoporphyrin Commercialization – Photodynamic Therapy Targets Superficial Cancers

Shanghai Pharmaceuticals Licenses MCB-166 Antidepressant from SJTU – Novel Mechanism Drug Candidate Targets Mental Health Pipeline

Insilico Medicine Launches PandaClaw – AI Agent Platform Transforms Biological Research with Natural Language Interface

Insilico Medicine Partners with ASKA Pharma – AI‑Driven Target Discovery Collaboration Targets Gynecological Diseases

Qilu Pharma’s QLS1317 Wins NMPA Approval – First‑in‑Class MSI‑H Targeted Therapy Enters Solid Tumor Clinical Trials

NHSA Unveils DRG 3.0 Grouping Scheme Roadmap – Systematic Upgrade Targets 2027 Implementation

Biocytogen Partners with Moonlight Bio – Antibody‑Cell Therapy Collaboration Targets Difficult‑to‑Treat Cancers

Innovent’s IBI302 Hits STAR Trial Primary Endpoint – Dual VEGF/Complement Inhibitor Shows 16‑Week Dosing and 50% Macular Atrophy Reduction in nAMD

Bio‑Thera Expands Intas Partnership to India – BAT2506 Golimumab Biosimilar Now Licensed Across US, Canada, and India

Sanofi Upgrades Shanghai R&D Center to Legal Entity – Largest China Translational Medicine Hub Anchors Global Network

RemeGen Secures Fourth NMPA Approval for Disitamab Vedotin – HER2‑Low Breast Cancer with Liver Metastases Indication Expands ADC Franchise

You Missed

Salubris Pharma Licenses Sintanovo’s Peripherally Restricted KOR Agonist STC007 for Pruritus and Pain Across Greater China

China’s Largest Healthcare M&A Fund Acquires Pediatrix Therapeutics, Bolstering Pediatric Specialty Pharma Portfolio

Hansoh Pharma’s Uplizna Gains Third NMPA Approval in China for Generalized Myasthenia Gravis, Expanding CD19 Antibody Franchise

Insilico Medicine and Eli Lilly Forge $2.75B AI Drug Discovery Partnership, Centered on Best-in-Class Oral Therapeutic